) recently announced that its oncology candidate, EC0652,
achieved key objectives in a phase 0 study. Endocyte is
developing the candidate as a treatment of patients suffering
from prostate cancer.
EC0652 is a diagnostic imaging agent that targets prostate
specific membrane antigen (PSMA), a protein expressed on cancer
cells which originates from the prostate as well as on tumor
Endocyte also has plans to advance its corresponding
therapeutic agent, EC1069. EC1069 is a proprietary PSMA-targeted
small molecule drug conjugate (SMDC) linked with the anti-cancer
drug tubulysin. Endocyte plans to file an Investigational New
Drug (IND) application for EC1069 by the end of this year.
Meanwhile, the company's focus remains on its oncology
candidate, vintafolide (MK-8109/EC145). Last year, the company
submitted a marketing authorization application (MAA) for the
candidate in the EU. Endocyte is also looking for EU approval of
an investigational companion diagnostic imaging agent
etarfolatide (EC20) along with vintafolide. Both the candidates
were granted orphan drug status in the EU.
Endocyte and its partner,
Merck & Co. Inc.
), are looking to get vintafolide approved as a treatment of
patients suffering from folate-receptor positive
platinum-resistant ovarian cancer in combination with pegylated
liposomal doxorubicin (PLD).
We remind investors that the oncology market is extremely
competitive with the presence of companies like
We expect investor focus to remain on the European Medicine
Agency's decision regarding the approval of vintafolide and
Endocyte carries a Zacks Rank #3 (Hold). However,
Valeant Pharmaceuticals International Inc.
), currently looks more attractive in the pharma sector with a
Zacks Rank #1 (Strong Buy).
ENDOCYTE INC (ECYT): Free Stock Analysis
MERCK & CO INC (MRK): Free Stock Analysis
(RHHBY): ETF Research Reports
VALEANT PHARMA (VRX): Free Stock Analysis
To read this article on Zacks.com click here.